Suppr超能文献

创新、机遇与挑战:预测特殊人群中药物代谢酶和转运体活性改变

Innovations, Opportunities, and Challenges for Predicting Alteration in Drug-Metabolizing Enzyme and Transporter Activity in Specific Populations.

机构信息

Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Waltham, Massachusetts (P.P.C., D.R.); Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland (V.A.); Department of Pharmaceutical Sciences, Washington State University, Spokane, Washington (B.P.); and Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, R&D, Stevenage, United Kingdom (K.T.)

Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Waltham, Massachusetts (P.P.C., D.R.); Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland (V.A.); Department of Pharmaceutical Sciences, Washington State University, Spokane, Washington (B.P.); and Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, R&D, Stevenage, United Kingdom (K.T.).

出版信息

Drug Metab Dispos. 2023 Dec;51(12):1547-1550. doi: 10.1124/dmd.123.001453. Epub 2023 Sep 29.

Abstract

Drug-metabolizing enzymes and transporters (DMETs) are key regulators of the pharmacokinetics, efficacy, and toxicity of therapeutics. Over the past two decades, significant advancements in in vitro methodologies, targeted proteomics, in vitro to in vivo extrapolation methods, and integrated computational approaches such as physiologically based pharmacokinetic modeling have unequivocally contributed to improving our ability to quantitatively predict the role of DMETs in absorption, distribution, metabolism, and excretion and drug-drug interactions. However, the paucity of data regarding alterations in DMET activity in specific populations such as pregnant individuals, lactation, pediatrics, geriatrics, organ impairment, and disease states such as, cancer, kidney, and liver diseases and inflammation has restricted our ability to realize the full potential of these recent advancements. We envision that a series of carefully curated articles in a special supplementary issue of will summarize the latest progress in in silico, in vitro, and in vivo approaches to characterize alteration in DMET activity and quantitatively predict drug disposition in specific populations. In addition, the supplementary issue will underscore the current scientific knowledge gaps that present formidable barriers to fully understand the clinical implications of altered DMET activity in specific populations and highlight opportunities for multistakeholder collaboration to advance our collective understanding of this rapidly emerging area. SIGNIFICANCE STATEMENT: This commentary highlights current knowledge and identifies gaps and key challenges in understanding the role of drug-metabolizing enzymes and transporters (DMETs) in drug disposition in specific populations. With this commentary for the special issue in , the authors intend to increase interest and invite potential contributors whose research is focused or has aided in expanding the understanding around the role and impact of DMETs in drug disposition in specific populations.

摘要

药物代谢酶和转运体(DMETs)是治疗药物药代动力学、疗效和毒性的关键调节剂。在过去的二十年中,体外方法学、靶向蛋白质组学、从体外到体内外推方法以及综合计算方法(如基于生理学的药代动力学建模)的显著进展,无疑提高了我们定量预测 DMETs 在吸收、分布、代谢和排泄以及药物相互作用中的作用的能力。然而,关于特定人群(如孕妇、哺乳期、儿科、老年、器官损伤以及癌症、肾脏和肝脏疾病和炎症等疾病状态)中 DMET 活性改变的数据稀缺性限制了我们充分发挥这些最新进展潜力的能力。我们设想,将在 的一个特刊中精心策划的一系列文章,将总结在体内、体外和体内方法来描述 DMET 活性改变以及定量预测特定人群中药物处置方面的最新进展。此外,该特刊将强调当前科学知识差距,这些差距构成了充分理解特定人群中改变的 DMET 活性的临床意义的巨大障碍,并突出了多利益相关者合作的机会,以推进我们对这一快速发展领域的集体理解。意义陈述:本评论强调了当前的知识,并确定了在理解药物代谢酶和转运体(DMETs)在特定人群中的药物处置中的作用方面的知识差距和关键挑战。通过这篇评论为 中的特刊,作者旨在提高兴趣并邀请潜在的贡献者,其研究重点是或有助于扩大对 DMETs 在特定人群中的药物处置中的作用和影响的理解。

相似文献

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验